Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.05p +0.14% 37.00p 36.10p 37.90p - - - 67,616 16:35:12
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 41.6 4.3 59.0 0.6 169.32

Ekf Diagnostics Share Discussion Threads

Showing 1476 to 1496 of 1500 messages
Chat Pages: 60  59  58  57  56  55  54  53  52  51  50  49  Older
DateSubjectAuthorDiscuss
21/9/2018
07:36
An EKF sponsored article highlighting the importance of lab quality POCT HbA1c results, which EKF's Quo-Lab achieves - Point-of-Care HbA1c Testing Against International Quality Targets Sponsored Content by EKF Diagnostics Sep 20 2018 Full article, News-Medical.Net - https://tinyurl.com/Lab-Quality-HbA1c-POCT
wan
19/9/2018
07:43
Today's solid Results demonstrating very good profitable underlying growth, shows a resilient business with excellent near term growth prospects that should, at the very least, continue during the remainder of this year, but accelerate at a fair clip during 2019. The potential from RenalytixAI adds another dimension to the above.
wan
12/9/2018
07:46
Following on from the FDA post above - UK follows suit, or at least makes an important start - Guidance Initial code of conduct for data-driven health and care technology Published 5 September 2018 Introduction Today we have some truly remarkable data-driven innovations, apps, clinical decision support tools supported by intelligent algorithms, and the widespread adoption of electronic health records. In parallel, we are seeing advancements in technology and, in particular, artificial intelligence (AI) techniques. AI is being used on this data to develop novel insights, tools to help improve operational efficiency and machine learning driven algorithms, and clinical decision support tools to provide better and safer care. This presents a great opportunity, but these techniques are reliant on the use of data that the NHS and central government have strong duties to steward responsibly. Data-driven technologies must be harnessed in a safe, evidenced and transparent way. We must engage with patients and the public on how to do this in a way that maintains trust. Our responsibility as an internationally trusted health and social care system is to use all the tools at our disposal to improve the quality and safety of care. We are working to build new ways to support the development of new data-driven innovations through programmes such as Local Health and Care Record Exemplars, Digital Innovation Hubs and NHS Test Beds. At the same time, we have collated a set of principles outlined in this code of conduct to ensure that this opportunity can be combined with responsibility, to result in partnerships that deliver benefits to patients, clinicians, industry and the health and care system as a whole. To achieve these ends, the code will: provide clarification of: what we expect from suppliers of data-driven technologies what the government will do to support and encourage innovators in health and care, including the development of trusted approval systems and a coherent pathway for suppliers to enter the market provide the basis for ongoing engagement and conversation on how we should use new technology to provide better and more sustainable services, with: our partners in academia, industry and the health and care system patients clinicians the wider public provide the basis for the health and care system and suppliers of digital technology to enter into commercial terms in which the benefits of the partnerships between technology companies and health and care providers are shared fairly We are launching the code in an initial form and encourage and welcome comment and feedback to improve and strengthen its contents. We also encourage its use – it provides principles that we want our suppliers to live by and that those involved in the commissioning and procurement of innovative, digital technologies and services should look for. Above all, it seeks to provide a basis to deepen the trust between citizen, clinician and the wider health and care system. We should not wait to take this opportunity. Please note that this code does not replace or change any existing regulatory requirements. We expect developers of data-driven technologies to work closely with health and care providers to ensure the safe implementation of technology and manage risks to the safety and quality of care in accordance with the expectations set out by the health and care system regulators. Health and care data must be used in accordance with the common law duty of confidence. The way ahead As of now, the code is voluntary, but any organisation that wishes to sign up to the code immediately can, and is encouraged to. We want to ensure that we give our stakeholders the opportunity to co-design the final version with us. We want the code to be something that technology providers want to sign up to, to demonstrate their world-leading approach. Alongside this, we are conducting a formal review of the regulatory framework and assessing commercial models used in technology partnerships. This is to ensure that issues including, but not limited to, bias, transparency, liability and accountability are appropriately accounted for. After the conclusion of these exercises, we aim to have identified how to constructively enforce these standards, as well as provide commercial support for trusts that wish to enter into partnerships with industry. We have therefore published the code online with the ability for you to feed back to us via a questionnaire. We will republish this document in December, at which point the code will become a collaboratively agreed standard for technology partnerships. We are considering how best to develop the code over time, including the setting up of a partnership support service and development of a Kitemark scheme for the code, underpinned by a robust application and evaluation process. We welcome comment from all stakeholders on these ideas. Full release (a long read) - https://tinyurl.com/y9yxs65q
wan
05/9/2018
07:51
FDA Sets Goals for Big Data, Clinical Trials, Artificial Intelligence The FDA is seeking to speed up innovations in clinical trials, medical product development, and artificial intelligence using cost-effective strategies and big data. By Jessica Kent September 04, 2018 - The FDA is turning to cost-effective strategies and big data to accelerate clinical trial efficiency, medical product development, and innovations in artificial intelligence, according to a recent blog post from FDA Commissioner Scott Gottlieb, MD. “Our longstanding goal for medical care is to ensure that the right drug or device is delivered to the right patient at the right time. This vision is increasingly possible with the innovative products that are becoming available,” he wrote. “These new technologies offer transformative opportunities. But they also challenge the US Food and Drug Administration (FDA) to modernize its approach to evaluating new innovations.” The FDA is looking to enhance innovation in areas that currently lack regulatory standards, including the field of artificial intelligence (AI). “AI holds enormous promise for the future of medicine. We’re actively developing a new regulatory framework to promote innovation in this space and support the use of AI-based technologies,” Gottlieb said. Full story, Healthcare Analytics - https://tinyurl.com/FDA-Artificial-Inteligence
wan
03/9/2018
07:31
Having checked the previous announcements/updates, there appears to be something new within the detail of Friday's announcement; "patient stratification for drug clinical trials and drug target discovery." which suggests to me that drug companies would likely to be very interested in working with Renalytix. In my view, that possibility is another good reason for holding onto any resulting shares issued.
wan
23/8/2018
08:46
Further evidence in support for diagnosing diabetes via HbA1c, which is going to align very well with EKF's HbA1c franchise, perhaps especially so in the US - First-Trimester HbA1c Predicts Gestational Diabetes Miriam E. Tucker August 22, 2018 Measurement of hemoglobin A1c (HbA1c) during the first trimester of pregnancy may aid in early detection of women at risk for gestational diabetes, new research suggests. The findings, from two prospective ethnically diverse cohorts of nearly 3000 pregnant women, were published online August 16 in Scientific Reports, by Stefanie N. Hinkle, PhD, of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, Maryland, and colleagues hxxps://www.medscape.com/viewarticle/901057
wan
16/8/2018
07:48
Another recent successful fund raise also highlights the level of interest - Intelligent healthcare company Rinicare announces completion of financing Rinicare raises money to support the commercialisation of its digital healthcare portfolio Manchester, UK, 15th August 2018 - Rinicare Limited, a leading intelligent healthcare company has announced the completion of its financing round by welcoming new investors Catapult Ventures and NPIF - Mercia Equity Finance, which is managed by Mercia Fund Managers and part of the Northern Powerhouse Investment Fund. The funding will be used to support the commercialisation of Rinicare’s digital healthcare portfolio, which is designed to provide solutions that improve outcomes and reduce costs in a number of settings such as emergency, primary and community care as well as progress its AI-powered predictive algorithm for intensive care. Healthcare providers around the world face the challenge of maintaining sustainable healthcare systems in light of an ageing population and continuously increasing costs. Rinicare’s approach to addressing these challenges is based on a collaborative effort with clinicians and end users to design advanced wireless communications, innovative prediction algorithms and enhanced software technology solutions that demonstrably improve outcomes and reduce healthcare costs. The company markets its wireless physiological signs technology (PRIME) and its falls prevention system (SAFE) globally in a number of healthcare solutions, which are tailored to individual needs. In addition to its expanding marketed solutions, Rinicare is developing its AI predictive system, Stability, which is initially focused at intensive care and addresses a global market for predictive healthcare analytics. This fast emerging area of healthcare is estimated to grow at a compound annual growth rate of over 25%, reaching an estimated global market value of $24.6billion by 2022. Stuart Hendry, CEO of Rinicare, commented: “We are very pleased to welcome such high-quality investors in this financing round. We will be using proceeds to support the ongoing commercialisation of our PRIME and SAFE based healthcare solutions in the UK and abroad as well as continuing with the development of world-leading Stability AI intensive care programme that has already captured data from several thousand intensive care patients.” Dr Vijay Barathan, Life Science Partner, Catapult Ventures said: “We are excited to work with Rinicare as they commercialise their intelligent health product portfolio in the UK and international healthcare markets. Each product represents an innovative solution and significant market opportunity.” Dr Mark Wyatt, Investment Director at Mercia, said: “I am looking forward to working with the Rinicare team, and I am excited to see their technologies drive efficiency gains and patient benefits into the healthcare system.” Sue Barnard, Senior Relationship Manager at British Business Bank, said: “The healthcare market is evolving rapidly, and is expected to grow significantly over the next few years. The North is home to many innovative businesses in this space, such as Rinicare, and NPIF is pleased to support those looking to enter the next phase of growth.” The Northern Powerhouse Investment Fund project is supported financially by the European Union using funding from the European Regional Development Fund (ERDF) as part of the European Structural and Investment Funds Growth Programme 2014-2020 and the European Investment Bank. hxxp://www.rinicare.com/news/press-releases/item/48-intelligent-healthcare-company-rinicare-announces-completion-of-financing
wan
16/8/2018
07:29
An interesting and balanced article on AI in healthcare - How Does AI Fit Into Health Care's Priorities Of 2018? Interest in artificial intelligence (AI) is exploding, with Accenture forecasting that AI in health care will grow to $6.6 billion in a few short years, at a 40% annual compounded growth rate. Accenture also believes this technology will enable an opportunity for $150 billion in industry savings. So, is this hype justified? The short answer is yes, but it belies a much deeper question: How do we weed out the hype and determine exactly what is the most effective role for AI so that we make the rest of 2018 a year for positive change and not disruptive chaos? Full story - https://tinyurl.com/Healthcare-and-AI
wan
15/8/2018
15:38
Thanks Wan, I agree - let’s hope the market realizes this at some stage...
cisk
15/8/2018
11:34
Cisk...The BOD's appear confident that there is significant upside, and given the other news flow centered around AI in healthcare, combined with the fact that the soluble Tumour Necrosis Factor Receptor 1 (sTNFR1) biomarker assets are held at zero on EKF's balance sheet, my guess is that we are talking more than just a few pennies per share. Sensyne raised £60m and subsequently realised a £225m market cap. Renalytix is looking to raise around £25m, so based on this being circa 40% of what Sensyne raised and given the similarities, could we then arrive at a market cap of £90m? Whatever the initial value arrived at, 59.18% will be attributable to EKF, in this case £53m which equates to circa 11.5p, but for the exercise let's round that down to 10p, which I think may prove to be conservative!
wan
15/8/2018
08:14
Wan, what’s your optimistic value of RenalytixAI per share? Impossible to gauge I know at this stage - so purely blue sky...
cisk
15/8/2018
07:49
Readers may be interested by the news of the successful floating of medical artificial intelligence company Sensyne Health in London with a capitalisation of £225m. The initial public offering on Aim raised £60m through a placing with institutional investors. 14th August 2018 Drayson floats medical AI group Sensyne Health on Aim Initial public offering raises £60m via placing with institutional investors Clive Cookson, Science Editor YESTERDAY Paul Drayson, biotech entrepreneur and former UK science minister, has floated his medical artificial intelligence company Sensyne Health in London with a capitalisation of £225m. Full story FT.Com - https://tinyurl.com/Healthcare-AI-Floatation I did a quick comparison between Sensyne Health and RenalytixAI - Sensyne has exclusive partnerships with a small number of NHS trusts. Three deals have been agreed so far with Oxford university Hospitals, South Warwickshire and Chelsea & Westminster trusts, the target is to work with 6 trusts around the UK. Sensyne's focus is on the chronic diseases that place the greatest burden on the NHS e.g. lung disease, cardiovascular disease, cancer and immunological diseases like diabetes. Apparently talks are under way with drug companies seeking to work with Sensyne. One deal has been signed with an unnamed company and six more are under negotiation. RenalytixAI has an exclusive global licence with Mount Sinai which provides access to its patient database and leading clinicians. Mount Sinai will also provide laboratory services. Mount Sinai is one of the largest health systems in the USA. It employs more than 7,000 physicians across eight hospitals and has 2.6m out-patient visits across 300 locations. In total Mount Sinai employees 36,000 staff. Renalytix focus (initially?) is on kidney disease, which is a very large burden on healthcare systems worldwide. The potential of AI in healthcare is huge and the listing of Sensyne confirms there is strong institutional interest for AI in healthcare. Recall, that the Directors of EKF "continue to believe that the Renalytix AI business has the potential to deliver significant upside value for EKF shareholders." And yesterdays news certainly adds a lot of weight to their belief!
wan
13/8/2018
15:21
I mean 1.2- to 1.5p! THanks interstellar
silverfern
09/8/2018
19:06
I firmly believe this is now going north so my advice is to hang on for the ride and/or jump back in. A 510k approval for Quo-Test (plus cLIA waiver if they can get it) will mean serious increase in sales
interstellar
09/8/2018
16:55
Finally got back to where it was when I sold in 2014. THey seem to have got their act together after the appalling investments in the past. WHat's the consensus on future earning 1.2-1.5p for the current year? If so I'll be tempted to get back in.
silverfern
09/8/2018
07:55
Yes two lots of excellent news today, a solid trading update plus a new contract with a very large player, McKesson, which should give cause for an earning upgrade for the remainder of 2018 and 2109. Given the new relationship and contract for Diaspect, it now looks likely, in my opinion, that McKesson will also eventually get distribution rights for Quo-test. Both of which will be a significant driver of earning growth in 2019!
wan
09/8/2018
07:19
And ahead of expectations
gersemi
09/8/2018
07:18
Great development - Excellent contract - Looks as though turnround is now well under way and justifies recent strength of SP https://www.investegate.co.uk/ekf-diagnostics-hldg--ekf-/rns/diaspect-tm-mckesson-us-distribution-agreement/201808090700122695X/
pugugly
24/7/2018
09:13
I should have added the following info to the above post - Anemia in Chronic Kidney Disease What is anemia? Anemia is a condition in which the body has fewer red blood cells than normal. Red blood cells carry oxygen to tissues and organs throughout the body and enable them to use energy from food. With anemia, red blood cells carry less oxygen to tissues and organs—particularly the heart and brain—and those tissues and organs may not function as well as they should. How is anemia related to chronic kidney disease? Anemia commonly occurs in people with chronic kidney disease (CKD)—the permanent, partial loss of kidney function. Anemia might begin to develop in the early stages of CKD, when someone has 20 to 50 percent of normal kidney function. Anemia tends to worsen as CKD progresses. Most people who have total loss of kidney function, or kidney failure, have anemia.1 A person has kidney failure when he or she needs a kidney transplant or dialysis in order to live. The two forms of dialysis include hemodialysis and peritoneal dialysis. Hemodialysis uses a machine to circulate a person’s blood through a filter outside the body. Peritoneal dialysis uses the lining of the abdomen to filter blood inside the body. hxxps://www.niddk.nih.gov/health-information/kidney-disease/anemia
wan
24/7/2018
09:10
Today's news of a new distribution deal with Asahi Kasei Pharma Corp, a very large Japanese global player, suggests EKF have far more to offer than a play predominantly on point of care! Indeed the new test will provide yet another new line of revenue. Going forwards, it would also appear to dovetail rather well with RenalytixAI, which might mean others are also looking at deals with EKF, which sends a signal about the prospects for RenalytixAI and EKF as a whole!
wan
11/7/2018
16:16
who is selling 5 million shares I wonder?
9degrees
Chat Pages: 60  59  58  57  56  55  54  53  52  51  50  49  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20180924 19:08:43